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Abstract
Background—Important risk factors for esophageal adenocarcinoma (EA) and its precursor, 
Barrett’s esophagus (BE) include gastroesophageal reflux disease, obesity, and cigarette-smoking. 
Recently, genome-wide association studies have identified seven germline single nucleotide 
polymorphisms (SNPs) that are associated with risk of BE and EA. Whether these genetic 
susceptibility loci modify previously identified exposure-disease associations is unclear.
Methods—We analyzed exposure and genotype data from the BEACON Consortium discovery 
phase GWAS, which included 1516 EA case patients, 2416 BE case patients, and 2187 control 
participants. We examined the seven newly identified susceptibility SNPs for interactions with 
body mass index, smoking status, and report of weekly heartburn or reflux. Logistic regression 
models were used to estimate odds ratios for these risk factors stratified by SNP genotype, 
separately for BE and EA.
Results—The odds ratio for BE associated with at least weekly heartburn or reflux varied 
significantly with the presence of at least one minor allele of rs2687201 (nominal p-value=0.0005, 
false discovery rate=0.042). Odds ratios (95% confidence intervals) for weekly heartburn or reflux 
among participants with 0, 1, or 2 minor alleles of rs2687201 were 6.17 (4.91,7.56), 3.56 
(2.85,4.44), and 3.97 (2.47,6.37), respectively. No statistically significant interactions were 
observed for smoking status and body mass index.
Conclusion—Reflux symptoms are more strongly associated with BE risk among persons 
homozygous for the major allele of rs2687201, which lies ~75 kb downstream of the transcription 
factor gene FOXP1.
Impact—The novel gene-exposure interaction discovered in this study provides new insights to 
the etiology of esophageal adenocarcinoma.
Keywords
esophageal cancer; gastroesophageal reflux disease; gene-environment interaction; genome-wide 
association study; smoking
INTRODUCTION
The incidence of esophageal adenocarcinoma (EA), an infrequent but often lethal disease, 
has been rising sharply in the past four decades, especially among white populations in 
developed countries (1–6). The majority of EA cases arise from Barrett’s esophagus (BE), a 
precursor lesion defined by a specialized columnar metaplasia of the distal esophagus (7). 
BE and EA share many risk factors, including gastroesophageal reflux disease (GERD), 
European ancestry, male gender, obesity and tobacco smoking, although the magnitudes of 
these associations may differ for BE and EA (8–14). Population-based studies in the United 
States and Australia indicate that GERD symptoms, high body-mass, and tobacco smoking 
account for approximately 75% of the population risk for EA (10,12).
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Less is known about inherited genetic susceptibility to BE and EA. Using the candidate gene 
approach, a number of genetic association studies have investigated the role of genetic 
predisposition in several biological pathways (15–21). Recently, large genome-wide 
association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs) 
for BE (22–23), including variants in or near FOXF1, TBX5, GDF7, and the major 
histocompatibility complex (MHC) genes. Additional susceptibility loci for BE/EA were 
also identified in or near CRTC1, BARX1, and FOXP1 (24). These loci were close to or 
passed the stringent genome-wide significance threshold. Notably, the GWAS based on the 
Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) reported that risk of BE 
and EA is influenced by many germline variants of small effect and, perhaps not 
surprisingly, genetic heritability is largely shared between the two diseases (25).
Understanding the interplay between genetic susceptibility and epidemiologic risk factors 
will improve risk prediction and provide insights into disease pathogenesis, thereby 
increasing understanding of BE and EA etiology. Some gene-exposure interactions have also 
been identified using the candidate gene approach, e.g. smoking and variants of GSTM1, 
GSTT1 and VEGF (26–31). Few of the previously reported variants have been replicated 
and more systematic studies are warranted. The statistical power to detect a genome-wide 
gene-environment interaction is, however, typically low because of high variability in 
estimates of interactions and the stringent p-value correction required for genome-wide 
testing.
An alternative approach is to focus the search for gene-exposure interactions on genetic 
susceptibility loci with significant genome-wide associations. This approach is mostly driven 
by statistical considerations to increase the chances of discovery, and has been used 
successfully in past studies of breast cancer (32). If a genetic variant interacts with an 
exposure, it is quite plausible that the marginal genetic association, i.e. the genetic 
association observed across all exposure levels (ignoring gene-exposure interaction) will 
also be evident. Limiting the search for gene-exposure interactions to SNPs that already 
demonstrate significant marginal genetic associations decreases the risk of chance 
associations and reduces the multiple-testing burden (33–35). Furthermore, marginal genetic 
associations are independent of gene-environment interactions as long as they are assessed 
in nested models, so that a much reduced multiple-test penalty is required to test for gene-
environment interactions among SNPs that rank high in marginal association tests (33). This 
approach therefore presents a benefit in statistical power when compared to an agnostic 
genome-wide interaction search.
In this report, using BEACON consortium data, we examine gene-exposure interactions, 
focusing on the seven SNPs previously shown to be associated with BE or EA at or near 
genome-wide significance and confirmed in replication studies. The risk factors under 
investigation include body-mass index, cigarette smoking, and acid reflux or heartburn 
symptoms.
Materials and Methods
Study population and SNP genotyping—Information from participants with BE and 
EA, and from associated controls, was collected by BEACON investigators in 14 studies 
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conducted in Australia, Western Europe and North America. All EA and BE diagnoses were 
histologically confirmed. Detailed population characteristics and genotyping protocols have 
been previously described (24). Demographic and exposure data were harmonized into 
standard variables. Genotyping of DNA from buffy coat or whole blood was performed 
using the Illumina HumanOmni1-Quad platform. Quality assurance and quality control of 
genotyping calls followed standard procedures (36). All participants gave written informed 
consent, and the project was approved by the ethics review boards at each participating 
center as well as for the study overall at the Fred Hutchinson Cancer Research Center.
All 1516 EA case patients and 2416 BE case patients in the discovery phase of the 
BEACON GWAS were included in this investigation, together with 2187 control 
participants. Three control participants were excluded from BE analyses due to familial 
relation to cases. Although all study sites collected data on age, sex, BMI and smoking 
status, some did not ascertain history of heartburn or reflux. The missing status of major risk 
factors under investigation in this report has been tabulated in Supplementary Table 1. The 
vast majority of missing data occurred because not all variables were included in all study 
questionnaires.
Statistical methods—Seven SNPs confirmed as associated with risk of EA or BE (22–
24) were included in our analysis: rs3072 in 2p24.1 (GDF7), rs2687201 in 3p14 (FOXP1), 
rs9257809 in 6p21 (MHC), rs11789015 in 9q22 (BARX1), rs2701108 in 12q24.21 (TBX5), 
rs9936833 in 16q24 (FOXF1), and rs10419226 in 19p13 (CRTC1). The reported odds ratios 
for these SNPs can be found in Supplementary Table 2. Three established risk factors were 
investigated for potential interaction with the SNPs: cigarette-smoking, BMI (weight (kg)/
height2 (m2)), and gastroesophageal reflux symptoms. These variables were coded as ever 
smoking (yes or no), BMI (<25, ≥25-<30, ≥30 kg/m2) and at least weekly heartburn or 
weekly reflux (yes or no). The definition of gastroesophageal reflux symptoms has been 
previously described (50). For each of these variables, logistic regression models were fitted 
to assess separately the risks of BE and EA. Each model included age, sex, the first four 
principal components (PC1-PC4) derived using genome-wide SNP data to account for 
population stratification by ancestry (24), the environmental exposure under investigation, a 
binary genotype indicator (0/1) for the presence of at least one minor allele of the given 
SNP, or a continuous genotype variable with discrete values 0, 1, or 2, and the product term 
of the environment exposure and genotype variable. The statistical significance of the 
interaction was assessed by a 1 degree-of-freedom (df) statistic for equal odds ratios 
between participants without the minor allele and participants with one or two copies of the 
minor allele, or the odds ratio associated with 1 additional minor allele. Although correlated, 
these two types of interaction tests explore parsimoniously the unknown true functional form 
of the interactions under investigation. The conservative Bonferroni correction for multiple 
testing was conducted for the 84 tests of gene-exposure interactions between 7 SNPs and 3 
risk variables, two outcomes (BE and EA), as well as interaction by the presence of the 
minor allele and by the trend interaction test. The false discovery rate (FDR) was computed 
for each of the nominal p-values for interaction (37). A sensitivity analysis was conducted to 
assess the impact of missing data in risk factors. Inverse probability weighted logistic 
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regression models were fitted, in which the weight is the inverse of the probability of being 
observed given age, gender, site, genotype and the top four principal components.
After examining interactions for each SNP-exposure pair, one at a time, additional analyses 
were conducted for SNP-exposure pairs that satisfied the criterion of family-wise error rate 
<0.05 after Bonferroni correction. To control for potential confounding from correlated risk 
factors, a logistic regression model was fitted to assess the three interaction terms between a 
SNP and the three risk variables, namely BMI, cigarette-smoking, and at least weekly 
heartburn or acid reflux, controlling for age, sex, the main effects of the SNP and risk 
factors, and the top four principal components.
Association analyses were conducted for imputed SNPs based on the 1000 Genomes project 
around any genotyped SNPs that showed significant interactions with one of the three risk 
factors. The details of the imputation procedure were presented previously (24).
RESULTS
Characteristics of participants in this study have been described elsewhere (24). Table 1 lists 
the associations of the three studied risk factors for EA and BE, adjusted for age and sex. 
The odds ratios for BE were generally larger than those for EA, except for cigarette 
smoking.
Figure 1 shows the q-q plot of p-values for each SNP and exposure pair, and for EA and BE 
separately. The p-values for the two types of interaction tests were split due to potentially 
high correlation between the two tests. As a comparison, a randomly selected set of seven 
SNPs from the BEAGESS study was assessed for interactions with the three exposures. The 
observed p-values were generally smaller than the expected p-values from the random set, 
possibly because of random noise and correlation of these statistics. Two SNPs had 
interaction p-values <0.05 (Table 2, equality test and trend test) and deviated significantly 
from the diagonal line in the q-q plot. The first SNP, rs2687201 (G/T, major and minor plus 
strand allele), lies near the FOXP1 gene, and the second, rs10419226 (C/A, major and minor 
plus strand allele), is located near the CRTC1 gene. Both SNPs were identified in the 
BEAGESS study (24).
The upper half of Table 2 shows the odds ratios of the three risk factors for groups with 0, 1, 
or 2 minor alleles of rs2687201 separately for BE and EA. The interaction between 
rs2687201 (G/T, major and minor plus strand allele) and GERD in relation to the risk of BE 
had the smallest p-value (0.0005), which is statistically significant under Bonferroni 
correction for 84 comparisons (P<5.95 x 10−4). The presence of at least one minor allele of 
rs2687201 appeared to decrease the magnitude of disease risk associated with GERD. The 
interaction of this SNP with ever smoking reached borderline statistical significance, 
whereas the association of BMI with risk of BE did not appear to vary substantially with 
rs2687201 genotype. The interactions of this SNP with exposures on the risk of EA were not 
statistically significant, although the patterns of the odds ratios among the three genotype 
groups were similar to those for BE; having one or two minor alleles generally decreased the 
magnitude of risk associated with reflux/heartburn and smoking. The interaction between 
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BMI and this variant in relation to EA risk was of borderline nominal significance (p=0.08), 
and this association was also in the same direction as that for BE risk. In sensitivity analyses, 
where the missing data in risk factors were accounted for by the inverse probability 
weighting method, the interaction between rs2687201 and GERD remained statistically 
significant (Supplementary Table 3). In a separate analysis, where BE and EA case 
participants were combined into a single case group, the significance level of the interaction 
between rs2687201 and GERD decreased (Supplementary Table A4). In results not shown, 
the interaction odds ratios in the three continents did not differ significantly (p=0.54).
The lower half of Table 2 shows the results for rs10419226 (C/A, major and minor plus 
strand allele). The smallest p-values occurred for the interaction of this SNP with GERD in 
association with EA risk (nominal p=0.01). The FDR for this interaction was 0.28.
In Table 3, the three risk factors were investigated simultaneously in one logistic regression 
model for their interactions with the rs2687201 variant, the only SNP with an interaction P 
value satisfying the Bonferroni significance threshold. This analysis helped to differentiate 
the independent contributions of the risk factors and their interactions since the three risk 
factors were correlated across the study populations. The p-value for the interaction with 
GERD remained nominally statistically significant (p=0.001), whereas the statistical 
significance of the interaction between the SNP and ever-smoking decreased when 
compared to the results in Table 2. These findings suggest that the newly discovered 
interaction between the SNP and GERD appears unlikely to be significantly confounded by 
the other two risk factors.
Table 4 shows odds ratios stratified by rs2687201 genotype and GERD status, adjusted for 
age, sex, and the top four principal components. Participants without minor alleles and 
without GERD comprised the reference group. The genetic relative risk (GRR) in the 
absence of GERD was 1.50, a statistically significant elevation of BE risk (nominal p-value 
= 0.00004). GERD increased the risk of BE substantially, regardless of the genotype group. 
The odds ratio for GERD-positive participants with at least one copy of the minor allele was 
less than that observed for GERD-positive participants homozygous for the major allele.
Figure 2 shows the regional interaction associations around rs2687201, including both 
genotyped and imputed SNPs. Of the 2017 adjacent SNPs assessed, a cluster of adjacent 
imputed SNPs with correlations (r2) >0.6 showed higher levels of significance in their 
interactions with GERD. The smallest nominal p-value obtained was for rs7638679 
(P=0.00006, Supplementary Table 5), which was much more statistically significant than 
that observed for rs2687201. The rs7638679 variant is situated ~50 kb away from the 
FOXP1 3′UTR.
DISCUSSION
We systematically investigated interactions between known risk factors for BE and EA and 
previously identified genome-wide significant associations in germline susceptibility. We 
found that rs2687201 (G/T, major and minor plus strand allele), a SNP on chromosome 3 
near the FOXP1 gene, modifies the association between gastroesophageal reflux disease and 
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risk of BE. None of the SNPs showed evidence of statistically significant interactions with 
BMI and smoking. As reported in our GWAS analysis of genetic effects alone (24), the 
rs2687201 polymorphism was associated with increased risk of BE and EA when the two 
diseases were combined into a single case group (OR=1.14).
The rs2687201 variant (chromosome 3p13) is located 75 kb distal to the FOXP1 3′UTR, in a 
~1-Mb intergenic region containing several pseudogenes (RNPC3P1, UQCRHP4, 
COX6CP6, HMGB1P36) and a predicted ~130-bp “novel miRNA” locus (AC096971.1) 
(Figure S1). Based on data from the 1000 Genomes Project (38), rs2687201 is in strong 
linkage disequilibrium (LD) (r2>0.8) with ~60 other SNPs, located within 30–60 kb (20 
SNPs with r2>0.94). rs2687201 is situated within a 1600-bp region characterized as 
heterochromatin in esophageal tissue, according to chromatin state segmentation data 
derived from the NIH Roadmap Epigenome Project (39). DNA regulatory motifs for 
multiple transcriptional regulators (e.g., CPHX, IK-2, ZNF143, HOXA9/10, MEF2, CTCF, 
RAD21, YY1, and NF-κB) are predicted to be altered by rs2687201 or other nearby variants 
in high LD (r2>0.90) (40). Data derived from cell lines analyzed in the ENCODE project 
indicate recruitment of several transcription factors (CEBPB, CJUN, P300, RAD21, STAT3) 
to recognition sequences within 4–8 kb (41).
Further assessment of the 13 imputed SNPs with more significant interaction P values than 
rs2687201 revealed that several of these variants (eg, rs2597312, rs7611254, rs1522554) are 
situated in putative enhancer sequences according to data from the Roadmap Epigenome 
Project (Supplementary Table 6.1); most of the 13 SNPs also appear to alter predicted DNA 
regulatory motifs. Expression quantitative trait locus (eQTL) analyses using the Genotype-
Tissue Expression (GTEx) Project resource (42) provided some evidence that eight of these 
13 SNPs may be associated (P<0.05) with altered FOXP1 expression levels in esophageal 
mucosa (Supplementary Table 6.2). Cautious interpretation is required, however, given the 
sizable number of comparisons and relatively weak P values. The precise functional effects 
of rs2687201 and/or linked variants on expression levels of FOXP1 or other neighboring loci 
remain to be determined. While biological characterization will require experimental follow-
up studies, a potential regulatory role for several of these SNPs appears plausible.
The FOXP1 gene encodes a member of the Forkhead box (FOX) family of transcription 
factors, which share an evolutionarily conserved “winged-helix” DNA binding domain and 
function as versatile regulators of a wide range of biological processes, including 
development and cancer (43–45). Knockout studies in mice demonstrated that FOXP1 and 
FOXP2 cooperatively regulate lung and esophageal development (46), while human FOXP1 
was first identified as a candidate tumor suppressor gene on chromosome 3p, a region 
known to exhibit loss of heterozygosity in many tumors, and in pre-malignant epithelial 
lesions of the oral cavity, breast, and cervix (47). In subsequent studies, expression of 
FOXP1 was associated with improved survival in breast cancer (48), but reduced survival in 
diffuse large B-cell lymphoma (49). FOXP1 appears to play opposing roles in different 
tissues and functions as either a tumor suppressor or oncogene depending upon context (50). 
It is interesting to note that genetic variation (rs9936833) in proximity to another FOX 
family member, FOXF1, has also been associated with altered risk of BE (22). While 
significant GxE interactions were not observed between this variant and reflux, BMI, or 
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smoking, our present findings for FOXP1 provide further evidence implicating FOX 
transcription factors in the modulation of disease risk for BE/EA, two conditions arising 
within an organ and tissue regulated by these same proteins during embryogenesis.
Several previous studies have pursued candidate-based GxE analyses of EA, and described 
potential interactions between GERD, smoking, or BMI and variants in a number of 
different genes related to detoxification, angiogenesis, DNA repair, apoptosis, and 
extracellular matrix degradation (27–31). These studies, however, were all limited by small 
sample sizes and lack of independent confirmation, and interactions in relation to risk of BE 
were not examined.
The present study has several strengths. First, our use of genetic and epidemiologic data 
from a large consortium-based GWAS of EA/BE (24) provided us with greater statistical 
power to detect GxE interactions than has been available in any previous study. Our decision 
to focus on the top marginal genetic signals identified in recent genome-wide analyses also 
eliminated the need to correct for a massive number of comparisons (33). Second, all 
genotyping from this GWAS was conducted on a single platform, and subjected to stringent 
quality-control procedures. Third, inclusion of both EA and BE cases in the current analysis 
enabled parallel assessment of GxE interactions for both an epithelial cancer and its 
metaplastic precursor lesion.
Our study also has certain limitations. We did not have a replication study for the newly 
discovered interaction due to lack of relevant exposure data in other studies. A full 
exploration of variants around the signal SNP and their functional consequences will further 
elucidate the mechanism of the interaction. The extent of missing data for environmental 
variables examined (34% missing BMI data among EA cases; 34% and 18% missing reflux 
data among EA or BE, respectively) considerably reduced statistical power for the indicated 
analyses, and may have resulted in some falsely negative GxE interactions. While systematic 
differences cannot be ruled out between included subjects with complete covariate data and 
those excluded because of missing data, the distributions of age, sex, and race were 
essentially comparable between these two groups, and most missing values for reflux 
occurred because certain study sites did not include this variable in their questionnaires. Our 
ability to detect GxE associations may also have been limited by the manner in which we 
modeled (or assessed) environmental exposures (e.g., at least weekly heartburn). Inclusion 
of more precise covariates, such as duration or timing of heartburn relative to diagnosis, 
might have helped capture additional interactions, but such information was often 
unavailable. While this analysis focused on seven SNPs previously shown to be associated at 
the genome-wide level with altered risk of EA or BE, a number of variants not satisfying this 
stringent threshold in marginal analysis may nonetheless exhibit significant interactions with 
reflux or BMI. Genome-wide GxE studies would be required to further explore this 
possibility. Lastly, some potential for measurement error of the exposures examined, 
especially reflux, should be acknowledged, given our consortium-based pooled study 
population. These exposures were ascertained across two decades in multiple studies on 
different continents. Nevertheless, an extensive effort was devoted to ensuring accurate data 
harmonization, as documented in several recent pooled analyses (51–53).
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Our report describes a novel interaction between an intergenic germline polymorphism and 
weekly reflux symptoms in relation to risk of Barrett’s Esophagus, the known precursor of 
esophageal adenocarcinoma. Further studies will be necessary to validate these findings in 
external populations and investigate the potential biological basis for differential disease risk 
associated with reflux in the presence of this variant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Quantile-quantile plots of 42 interaction p-values for seven single nucleotide polymorphisms 
(SNPs) under investigation. P-values were derived from interaction models in which SNP 
genotype was modeled as a continuous variable with values of 0/1/2 in (a). A randomly 
selected set of seven SNPs from the BEAGESS study were also plotted for comparison in 
(b) for the trend interaction test. P-values from the interaction test with SNP genotypes 
modeled as 0/1 were displayed in (c), along with the random set of seven SNPs in (d).
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Figure 2. 
Regional association plot of genotyped and imputed single nucleotide polymorphisms 
(SNPs) in proximity to rs2687201, summarizing evidence of interaction with at least weekly 
heartburn or reflux in relation to risk of Barrett’s esophagus (BE). The top portion of the 
figure has physical position along the x-axis, and -log10(p-value) for the interaction term on 
the y-axis. Each dot on the plot represents the p-value of the interaction between a SNP 
(coded as 0/1) and GERD in relation to BE risk. The index SNP is marked as a purple 
square, other genotyped SNPs are marked with squares, and imputed SNPs are marked by 
circles. The color scheme represents the pairwise correlation (r2) between a given SNP and 
the index SNP. Correlation was calculated using the HapMap CEU data. The bottom portion 
of the figure shows the position of genes across the region.
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